Tucatinib and trastuzumab achieved responses in 38% of HER2-amplified cancers but only 6% of HER2-mutated cases, suggesting amplification status may better predict benefit from this combination. (NPJ Precis Oncol)
HER2-targeted therapy active in amplified but not mutated tumors
The CRC Digest